<SEC-DOCUMENT>0001564590-21-013150.txt : 20210315
<SEC-HEADER>0001564590-21-013150.hdr.sgml : 20210315
<ACCEPTANCE-DATETIME>20210315160533
ACCESSION NUMBER:		0001564590-21-013150
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210309
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210315
DATE AS OF CHANGE:		20210315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACHIEVE LIFE SCIENCES, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	033-80623
		FILM NUMBER:		21741516

	BUSINESS ADDRESS:	
		STREET 1:		520 PIKE STREET
		STREET 2:		SUITE 2250
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		425-686-1500

	MAIL ADDRESS:	
		STREET 1:		520 PIKE STREET
		STREET 2:		SUITE 2250
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ONCOGENEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20080821

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>achv-8k_20210309.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
achv-8k_20210309.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): March 9, 2021 </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ACHIEVE LIFE SCIENCES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter) </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90.49%;">
<tr>
<td style="width:27.28%;"></td>
<td style="width:0.56%;"></td>
<td style="width:32.38%;"></td>
<td style="width:0.56%;"></td>
<td style="width:29.72%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:48pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:28.5pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">033-80623</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">95-4343413</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:48pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:48pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:28.5pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:28.5pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td colspan="3" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:22.78%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1040 West Georgia, Suite 1030</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;margin-right:22.78%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vancouver, B.C., Canada </p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V6E 4H1</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:22.78%;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (604) 210-2217 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N/A </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.05%;width:69.95%;">
<tr>
<td style="width:2.22%;"></td>
<td style="width:67.73%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.05%;width:70.23%;">
<tr>
<td style="width:2.22%;"></td>
<td style="width:68.01%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.05%;width:86.34%;">
<tr>
<td style="width:2.22%;"></td>
<td style="width:84.12%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.05%;width:85.79%;">
<tr>
<td style="width:2.22%;"></td>
<td style="width:83.56%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0.25pt;padding-Right:0.25pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.05%;width:95.86%;">
<tr>
<td style="width:35.98%;"></td>
<td style="width:26.69%;"></td>
<td style="width:33.19%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title of each class</font></p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Trading Symbol</font></p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of exchange on which registered</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, par value $0.001 per share</p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACHV</p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0.25pt;padding-Bottom:0.25pt;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The NASDAQ Capital Market</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="text-align:center;margin-top:4pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:6.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 9, 2021, the Board of Directors (the &#8220;<font style="font-weight:bold;font-style:italic;">Board</font>&#8221;) of Achieve Life Sciences, Inc. (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;) appointed Bridget Martell, M.D. and Cindy Jacobs, Ph.D., M.D., the Company&#8217;s current President and Chief Medical Officer, as directors, effective March 15, 2021. Neither Dr. Martell nor Dr. Jacobs has been appointed to a committee of the Board at this time.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66450216"></a><a name="_Hlk66450216"></a>In connection with Dr. Martell&#8217;s appointment to the Board, and in accordance with the Company&#8217;s non-employee director compensation program, she will receive an annual cash retainer of $[40,000] Board service. In addition, in accordance with the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;Plan&#8221;), on the effective date of her appointment, Dr. Martell will receive an initial stock option grant to purchase up to 5,650 shares of the Company&#8217;s common stock with an exercise price equal to the closing stock price as quoted on the Nasdaq Stock Market on the grant date. The options will vest and become exercisable monthly over 36 months commencing one month from the date of grant. Dr. Martell will also enter into the Company&#8217;s standard form of indemnity agreement. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.22%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Jacobs will not receive any compensation for her service as a director. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">There are no arrangements or understandings between either Dr. Martell or Dr. Jacobs and any other persons pursuant to which they were selected as a directors. There are also no family relationships between Dr. Martell or Dr. Jacobs and any director or executive officer of the Company, and Dr. Martell and Dr. Jacobs have no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.&nbsp;&nbsp;&#160;<font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.&nbsp;&nbsp;Financial Statements and Exhibits. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) <font style="margin-left:36pt;">Exhibits</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:9.84%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom"  style="width:2.66%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:87.5%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  style="width:9.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:87.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:-10pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:-10pt;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:-10pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:87.5%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:72pt;;text-indent:-72pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="achv-ex991_6.htm"><font style="text-decoration:underline;">Press Release of Achieve Life Sciences, dated March 15, 2021 </font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">________________________</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-right:6.67%;text-indent:0%;letter-spacing:-0.15pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-right:6.67%;letter-spacing:-0.15pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;">SIGNATURES</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:478.8pt;;">
<tr>
<td style="width:216.3pt;"></td>
<td style="width:262.5pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACHIEVE LIFE SCIENCES, INC.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;letter-spacing:-0.15pt;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 15, 2021</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;letter-spacing:-0.15pt;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John Bencich</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;letter-spacing:-0.15pt;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Bencich</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer (Principal Executive and Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>achv-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
achv-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwsm3oomx4zv000001.jpg" title="" alt="" style="width:94px;height:104px;"></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:16pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:4.66%;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-right:4.88%;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Achieve Life Sciences Announces Appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to Board of Directors </p>
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-right:4.88%;text-indent:0%;font-size:16pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">SEATTLE, Wash. and VANCOUVER, British Columbia, March 15, 2021<font style="font-weight:normal;"> - Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to the company&#8217;s Board of Directors, effective immediately. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are excited to welcome Dr. Martell and Dr. Jacobs to the board&#8221;, commented Rick Stewart, Achieve&#8217;s Executive Chairman of the Board of Directors. &#8220;Dr. Martell&#8217;s clinical development experience compliments that of Dr. Jacobs, providing the company with depth of knowledge, particularly in the field of addiction, which is critically important for our continued success.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Martell brings an impressive and diverse background of scientific, clinical, and leadership experience to the team. She is board certified in both Internal and Addiction Medicine, served over 20 years as a practicing physician at Yale, and remains active there as an Entrepreneur in Residence at the Office of Cooperative Research. She has been a pivotal leader in the development and success of numerous marketed products across multiple therapeutic categories and has held leadership and executive roles at Pfizer, Kura Oncology, and Juniper Pharmaceuticals. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Jacobs currently serves as Achieve&#8217;s President and Chief Medical Officer. In addition to her board appointment, she will continue in this role leading the regulatory and clinical development efforts for cytisinicline. Dr. Jacobs brings over 30 years of experience in the industry, leading multiple development programs and product regulatory approvals. She has previously held leadership and executive roles at OncoGenex, Corixa, and Immunex. <font style="Background-color:#FFFFFF;">Dr.&#160;Jacobs received her Bachelor&#8217;s in Microbiology from Montana State University, her Master&#8217;s and Ph.D. in Veterinary Pathology/Microbiology from Washington State University, and an M.D. from the University of Washington Medical School. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwsm3oomx4zv000002.jpg" title="" alt="" style="width:100px;height:111px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwsm3oomx4zv000001.jpg" title="" alt="" style="width:94px;height:104px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About Achieve and Cytisinicline&#160;<font style="font-weight:normal;">&#160;<br />Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.<sup style="font-size:85%;line-height:120%;vertical-align:top">1,2</sup>&#160;</font><font style="color:#2C2728;font-weight:normal;">More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Achieve&#8217;s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction, and has not been approved by the FDA for any indication in the U.S.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.11%;text-indent:-0.11%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-weight:bold;">Forward Looking Statements</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.11%;text-indent:-0.11%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development activities,&nbsp;&nbsp;the potential market size and market acceptance for cytisinicline, the potential benefits of cytisinicline&nbsp;&nbsp; and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Media Contact<font style="font-weight:normal;"> &#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Glenn Silver&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#0000FF;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Glenn.Silver@Finnpartners.com</font><font style="color:#000000;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(646)&#160;871-8485&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations Contact<font style="font-weight:normal;">&#160;<br />Jason Wong&#160;<br /></font><font style="text-decoration:underline;color:#0000FF;font-weight:normal;">jwong@bplifescience.com</font><font style="font-weight:normal;">&#160;&#160;<br />(415) 375-3340 ext. 4&#160;</font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gwsm3oomx4zv000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwsm3oomx4zv000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %( 28# 2(  A$! Q$!_\0
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MFBZ"S&44_P F;_GD_P#WS1Y,O_/-O^^:+H+,913_ "9?^>;?]\T>3+_SS?\
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MP5(R#5/^QM-_Y\;?_OV*OT4FD]QJ36S*']BZ9_SXV_\ W[%']BZ9_P ^-O\
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</PO-I!N+J^D\RZN/OD4444X125C.I5E.7,S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gwsm3oomx4zv000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwsm3oomx4zv000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %; 3D# 2(  A$! Q$!_\0
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M-144I1M$J#2=V?60I<U\J?\ "3Z]_P!!F_\ _ A_\:/^$GU[_H,W_P#X$O\
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MQ7_<L_\ O_\ _6H_X4]XK_N6?_?_ /\ K4>VI]P]G/L<#17??\*>\5_W+/\
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MJ?<7LY]C@:VO"_B"X\-Z[;W\+816 E7&=R'K^.*Z3_A3WBO_ )YV?_?_ /\
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MV\TM])FE:V?89%E #<9Z8]Z[;P]K":_H-IJB0M"MPFX1L<E>2.OX5\Y_$/\
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MJ4=E8J:1K-OK5J;BV60(#CYUP:Q?B""?#T>!G_2$[?6NIC15&%4#Z4.JL,,
M?K6DHMPLS*$U"HII;#8O]2G^Z*X?QCHKV=P-<TZ,B0?\?"K_ !#U_P :[P"D
M90RX(R**E-3C9CH5G2J<R./^'.3H$Q88)N&/Z"NAUK2HM8TR6SE. XR#Z$=#
M5Z-%5<*H ]J?1"FE#D85*SE5=1:.YYMINJZIX/?[#J5M))9!L1R+SCZ5M?\
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CCA>&SMF&UF'WL5Z+3$15&%4#Z4^BG#D3\QUJWM&E:R1__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
